



## STATEMENT

"Faes Farma has licensed a pharmaceutical product from its portfolio in Spain, for co-development with US based Marathon Pharmaceuticals.

Under this license agreement, Faes Farma will manufacture and export the finished product for its commercialization by Marathon in the US.

Marathon is planning to submit a new drug application for the product in the US in early 2016.

Faes Farma shall receive payments for the license agreement and for regulatory milestones, as well as royalties on local sales during the life of the agreement.

This project is a breakthrough for Faes Farma, as it shall be the first for the US, by far the largest pharma market worldwide. In the frame of this agreement, Faes Farma expects to have its plant approved by the US regulatory authority (US FDA), which shall potentially bring additional opportunities for Faes in this market. "

May 18<sup>th</sup> 2015